Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P61278 (
somatostatin
)
22,083
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The primary treatment for non-functioning pituitary tumors (NFPTs) is surgery, but it is often unsuccessful. Previous studies have reported that NFPTs express receptors for
somatostatin
(SST
1-5
) and dopamine (DRDs) providing a rationale for the use of dopamine agonists and
somatostatin
analogues. Here, we systematically assessed SST
1-5
and DRDs expression by real-time quantitative PCR (RT-qPCR) in a large group of patients with NFPTs (
n
= 113) and analyzed their potential association with clinical and molecular aggressiveness features. SST
1-5
expression was also evaluated by immunohistochemistry. SST
3
was the predominant SST subtype detected, followed by SST
2
, SST
5
, and SST
1
. DRD2 was the dominant
DRD
subtype, followed by DRD4, DRD5, and DRD1. A substantial proportion of NFPTs displayed marked expression of SST
2
and SST
5
. No major association between SST
s
and DRDs expression and clinical and molecular aggressiveness features was observed in NFPTs.
...
PMID:Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features. 3297 45
